Alopecia areata occurring during anti-TNF therapy: A national multicenter prospective study

Saved in:
Bibliographic Details
Published inJournal of the American Academy of Dermatology Vol. 70; no. 6; pp. 1146 - 1149
Main Authors Tauber, Marie, MD, Buche, Sébastien, MD, Reygagne, Pascal, MD, Berthelot, Jean-Marie, MD, Aubin, François, MD, PhD, Ghislain, Pierre-Dominique, MD, Cohen, Jean-David, MD, Coquerelle, Pascal, MD, Goujon, Elisa, MD, Jullien, Denis, MD, PhD, Brixi, Hedia, MD, Jeudy, Géraldine, MD, Guennoc, Xavier, MD, Martin, Antoine, MD, Brénaut, Emilie, MD, Hoppé, Emmanuel, MD, Bertolotti, Antoine, MD, Bardin, Thomas, MD, PhD, Delaporte, Emmanuel, MD, Allez, Matthieu, MD, PhD, Bachelez, Hervé, MD, PhD, Seneschal, Julien, MD, PhD, Viguier, Manuelle, MD, PhD
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.06.2014
Subjects
Adalimumab
Adult
Age Distribution
Alopecia Areata - chemically induced
Alopecia Areata - epidemiology
Alopecia Areata - physiopathology
Antibodies, Monoclonal, Humanized - administration & dosage
Antibodies, Monoclonal, Humanized - adverse effects
Antibodies, Monoclonal, Humanized - therapeutic use
Cohort Studies
Dermatology
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Follow-Up Studies
France - epidemiology
Humans
Incidence
Male
Middle Aged
Prospective Studies
Risk Assessment
Sex Distribution
Tumor Necrosis Factor-alpha - antagonists & inhibitors
France
Online AccessGet full text

Cover

More Information
Bibliography:SourceType-Other Sources-1
ObjectType-Article-2
content type line 63
ObjectType-Correspondence-1
ISSN:0190-9622
1097-6787
DOI:10.1016/j.jaad.2014.03.005